Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director · CEO and Director | March 02, 2018 | March 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date March 02, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.13 · Expires 2027-01-27 | Direct | 27,984 |
Reported balance
After 2018-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-02 · Grant · Acquired 27,984 · Balance 27,984 F1: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3.
F2: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3.
F3: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2018 Filed Mar 2, 2018 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 27,984 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001655 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,984 Underlying: Common Stock · 27,984 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 57,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000695 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,891 F1 · security: Restricted stock awards vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 3,278 | $60.04 | $196,811.12 |
DisclosureSEC source: 0001171843-17-006332 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,791 F1 · price: On October 24, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 3,278 shares in multiple trades ranging from $60.00 to $60.10. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 22,228 | $60.06 | $1,335,013.68 |
DisclosureSEC source: 0001171843-17-006236 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,069 F2 · price: On October 23, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 22,228 shares in multiple trades ranging from $60.00 to $60.22. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 5,991 | $60.04 | $359,699.64 |
DisclosureSEC source: 0001171843-17-006236 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,297 F1 · price: On October 20, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,991 shares in multiple trades ranging from $60.00 to $60.13. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 3,293 | $60.04 | $197,711.72 |
DisclosureSEC source: 0001171843-17-006128 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · price: On October 16, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 3,293 shares in multiple trades ranging from $60.00 to $60.14. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 5,216 | $60.11 | $313,533.76 |
DisclosureSEC source: 0001171843-17-006079 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,581 F2 · price: On October 13, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,216 shares in multiple trades ranging from $60.00 to $60.17. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 1,908 | $60.00 | $114,480.00 |
DisclosureSEC source: 0001171843-17-006079 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,797 F1 · price: On October 12, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 1,908 shares in a single trade at $60.00. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 63,799 | $50.79 | $3,240,351.21 |
DisclosureSEC source: 0001171843-17-004472 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,705 F1 · price: On July 27, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 63,799 shares in multiple trades ranging from $50.00 to $52.05. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 8,236 | $50.06 | $412,294.16 |
DisclosureSEC source: 0001171843-17-003991 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,504 F2 · price: On July 5, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 8,236 shares in multiple trades ranging from $50.00 to $50.25. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 22:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 5,965 | $50.00 | $298,250.00 |
DisclosureSEC source: 0001171843-17-003991 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,740 F1 · price: On July 3, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,965 shares in multiple trades ranging from $50.00 to $50.02. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:07 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 39,375 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001208 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000590 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.